Loading...
Over the past decade, technologic improvements have increased the precision with which prostate cancer external beam radiotherapy is administered, allowing higher doses while minimizing irradiation of normal tissue. Hypofractionated treatment of prostate cancer theoretically may improve outcomes while decreasing treatment times and costs and increasing patient tolerance.
To test this concept, investigators conducted a randomized, phase III, noninferiority trial of ultra-hypofractionated radiotherapy (42.7 Gy in 7 fractions, 3 days/week for 2.5 weeks) against conventional hypofractionated therapy (78.0 Gy in 39 fractions, 5 days/week for 8 weeks) without androgen deprivation therapy in 1180 men with intermediate-risk to high-risk prostate can…